Bausch + Lomb reports positive study results for Blink NutriTears
Seeking Alpha News (Thu, 25-Apr 12:33 PM ET)
FDA approves Amneal's generic version of OTC Narcan
Seeking Alpha News (Wed, 24-Apr 11:01 AM ET)
Analysts Conflicted on These Healthcare Names: Bausch Health Companies (BHC) and Enlivex (ENLV)
TipRanks (Tue, 23-Apr 6:30 AM ET)
Bausch Health to Announce First-Quarter 2024 Results on May 2
ACCESSWIRE (Thu, 11-Apr 4:23 PM ET)
ACCESSWIRE (Thu, 11-Apr 1:05 PM ET)
ACCESSWIRE (Thu, 11-Apr 8:02 AM ET)
Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
ACCESSWIRE (Fri, 5-Apr 6:15 PM ET)
ACCESSWIRE (Wed, 3-Apr 8:03 AM ET)
ACCESSWIRE (Tue, 2-Apr 8:03 AM ET)
Bausch Health Companies Inc is a global specialty pharmaceutical, consumer health, and medical device company with a focus on branded products for the gastroenterology, hepatology, neurology and dermatology markets. The company reports revenue in five segments: Salix; International; Solta Medical; Diversified Products and Bausch + Lomb. It generates maximum revenue from the Bausch + Lomb segment.
Bausch Health Companies trades on the NYSE stock market under the symbol BHC.
As of April 25, 2024, BHC stock price climbed to $8.62 with 2,735,191 million shares trading.
BHC has a beta of 2.01, meaning it tends to be more sensitive to market movements. BHC has a correlation of 0.15 to the broad based SPY ETF.
BHC has a market cap of $3.15 billion. This is considered a Mid Cap stock.
Last quarter Bausch Health Companies reported $2 billion in Revenue and $1.15 earnings per share. This beat revenue expectation by $108 million and exceeded earnings estimates by $.13.
In the last 3 years, BHC stock traded as high as $34.50 and as low as $4.00.
The top ETF exchange traded funds that BHC belongs to (by Net Assets): ACTV, PPH, DFIS, FDLS, PXF.
BHC has underperformed the market in the last year with a price return of +14.0% while the SPY ETF gained +23.6%. However, in the short term, BHC had mixed performance relative to the market. It has outperformed in the last 3 months, returning +7.2% vs +4.1% return in SPY. But in the last 2 weeks, BHC shares have been beat by the market, returning -3.4% compared to an SPY return of -2.1%.
BHC support price is $8.25 and resistance is $8.88 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHC stock will trade within this expected range on the day.